Investing
FTC Commissioners yet to meet on Amgen-Horizon deal – CNBC
© Reuters. FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/
(Reuters) – Commissioners at the U.S. Federal Trade Commission (FTC) have not yet met to discuss Amgen (NASDAQ:)’s acquisition of Horizon Therapeutics (NASDAQ:), CNBC reported on Tuesday.
The news comes a day after reports that the FTC is expected to file a lawsuit as early as Tuesday to block the $27.8 billion deal.
Read the full article here